Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Immix Biopharma, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 8 | 7 | −1 |
| Shares | 146.5K | 183.5K | +36.9K (+25.2%) |
| Value | $352.0K | $475.0K | +$123.0K (+34.9%) |
New holders (4)
Institutions that held Immix Biopharma, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 73,333 | $190.0K | 0.00% |
| Vanguard Group Inc | 50,905 | $132.0K | 0.00% |
| State Street Corp | 38,560 | $100.0K | 0.00% |
| UBS Group AG | 4,337 | $11.0K | 0.00% |
Sold out (5)
Institutions that held Immix Biopharma, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Renaissance Technologies LLC | 62,600 | $151.0K |
| Virtu Financial LLC | 23,515 | $57.0K |
| Citadel Advisors LLC | 21,713 | $52.0K |
| XTX Topco Ltd | 12,992 | $31.0K |
| BlackRock Inc. | 9,415 | $22.0K |